

Resource Summary Report

Generated by ASWG on Aug 15, 2026

PE Mouse Anti-Human CD34

RRID:AB_400371

Type: Antibody

Proper Citation

BD Biosciences Cat# 348057, RRID:AB_400371

Antibody Information

URL: http://antibodyregistry.org/AB_400371

Proper Citation: BD Biosciences Cat# 348057, RRID:AB_400371

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Comments: suggested use: Flow Cytometry

Antibody Name: PE Mouse Anti-Human CD34

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: 8G12

Antibody ID: AB_400371

Vendor: BD Biosciences

Catalog Number: 348057

Record Creation Time: 20250819T233916+0000

Record Last Update: 20250820T060022+0000

Ratings and Alerts

No rating or validation information has been found for PE Mouse Anti-Human CD34 .

No alerts have been found for PE Mouse Anti-Human CD34 .

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#).

Zhang P, et al. (2025) Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies. Cancer discovery.

Xu C, et al. (2022) Comprehensive multi-omics single-cell data integration reveals greater heterogeneity in the human immune system. iScience, 25(10), 105123.

Takayama N, et al. (2021) The Transition from Quiescent to Activated States in Human Hematopoietic Stem Cells Is Governed by Dynamic 3D Genome Reorganization. Cell stem cell, 28(3), 488.

Parveen S, et al. (2018) Establishment and characterization of induced pluripotent stem cells from placental mesenchymal stromal cells. Stem cell research, 27, 15.

Gomez Limia CE, et al. (2018) Characterization of a human induced Pluripotent Stem (iPS) cell line (INCABRi002-A) derived from a primary myelofibrosis patient harboring the 5-bp insertion in CALR and the p.W146X mutation in TP53. Stem cell research, 33, 130.

Gomez Limia CE, et al. (2017) Generation and characterization of a human induced pluripotent stem (iPS) cell line derived from an acute myeloid leukemia patient evolving from primary myelofibrosis carrying the CALR 52bp deletion and the ASXL1 p.R693X mutation. Stem cell research, 24, 16.